Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13386133 | 0.93 | BCHE (0.40) | PIK3CAMAPTALDH1A1LMNAGPR119 | |
| SCHEMBL13386210 | 0.92 | BCHE (0.42) | PIK3CAMAPTALDH1A1LMNAGPR119 | |
| SCHEMBL13386253 | 0.88 | BACE1 (0.41) | PDK2MAPTALDH1A1LMNAGPR119 | |
| SCHEMBL13386122 | 0.85 | BCHE (0.39) | PIK3CAALDH1A1LMNAGPR119USP30 | |
| SCHEMBL13386285 | 0.84 | BCHE (0.39) | PIK3CAMAPTALDH1A1LMNAGPR119 | |
| SCHEMBL2594780 | 0.81 | PDK2 (0.46) | PDK2MAPTALDH1A1LMNAGPR119 | |
| SCHEMBL8256409 | 0.81 | MAPT (0.54) | PIK3CAPDK2MAPTALDH1A1LMNA | |
| SCHEMBL15909028 | 0.79 | NR1H2 (0.43) | PIK3CAMAPTALDH1A1LMNAGPR119 | |
| SCHEMBL2585068 | 0.76 | SIRT6 (0.41) | PDK2MAPTALDH1A1GPR119BCHE | |
| SCHEMBL5234283 | 0.76 | PDK2 (0.55) | PDK2MAPTALDH1A1LMNAGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699241-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-8828986-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2699241-A1 | ANTIVIRAL COMPOUNDS | Prosetta Antiviral Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012145567-A1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270854-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270854-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | PIK3CA 3381/4885PDK2 1701/4885MAPT 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.